DiagnaMed Holdings Corp Stock Price, News & Analysis

DiagnaMed Holdings (OTCQB: DGNMF) has announced the issuance of equity incentives to align leadership interests with shareholders. The company granted 3,000,000 restricted share units (RSUs) and 2,500,000 stock options to directors, officers, and consultants.

The stock options have an exercise price of $0.05 per share with a three-year exercise period. The grants support DiagnaMed's advancement of natural hydrogen projects in Ontario, conducted in collaboration with INRS and QIMC partners, including ongoing deployment in Northern Ontario.

DiagnaMed Holdings Corp. (OTCQB: DGNMF) announced a leadership transition in its financial department. Jing Peng has stepped down from his position as Chief Financial Officer, effective immediately. The company has appointed Edward Low as Interim CFO, who brings significant experience in corporate finance and accounting for public companies.

Mr. Low will oversee DiagnaMed's financial operations during the transition period while the Board evaluates long-term leadership options. The company continues to focus on its hydrogen development initiatives and operational execution, particularly in Northern Ontario through its QIMC and INRS teams.

DiagnaMed Holdings Corp. (CSE: DMED) has launched a major hydrogen exploration campaign in Ontario in partnership with INRS and Quebec Innovative Materials Corp. The initiative will implement over 2,000 soil gas samples to identify high-potential natural hydrogen zones, replicating INRS-QIMC's successful exploration model from Quebec.

The exploration will be led by Dr. Marc Richer-Laflèche in collaboration with Temiscamingue First Nations. The program aims to leverage the proven geological model that demonstrated high hydrogen measurements and fault-controlled advection in Quebec. Additionally, the company announced the appointment of André Turmel to its Board of Directors, while Carlo Sansalone has stepped down.

DiagnaMed Holdings Corp. (DGNMF) is advancing its natural hydrogen and helium exploration program in Ontario's Timiskaming district. The company, collaborating with INRS and Quebec Innovative Materials Corp., has begun reviewing geological data to identify high-priority targets across their claims. The exploration strategy focuses on areas with specific geological characteristics including Precambrian bedrock, Paleozoic formations, active rift systems, and fault systems conducive to gas migration. The program builds on a successful model previously used in the St-Bruno-de-Guigues hydrogen discovery in Quebec. The exploration area covers Armstrong, Brethour, Whitewood Grove, and Tomstown in Northern Ontario. Additionally, DiagnaMed has engaged Independent Trading Group (ITG) for market-making services at C$5,000 per month to enhance share liquidity on the CSE.

DiagnaMed Holdings Corp. (DGNMF) has appointed John Karagiannidis as its new President and CEO, replacing Fabio Chianelli who will transition to a Board Director role. Karagiannidis will maintain his position as President and CEO of Quebec Innovative Materials Corp. (QIMC), strengthening the strategic partnership between both companies. The leadership change aims to accelerate DiagnaMed's growth in Ontario's emerging hydrogen sector, supported by the Ontario government's recent $30 million Hydrogen Innovation Fund allocation. DiagnaMed has secured strategic claims in Ontario's Temiscamingue hydrogen district and plans to initiate a comprehensive soil sampling program in collaboration with INRS and Temiscamingue First Nations. The company's focus aligns with industry forecasts projecting up to 135,000 Canadian jobs in the hydrogen economy.

DiagnaMed Holdings Corp. (DGNMF) has announced a strategic acquisition in Ontario to demonstrate its proprietary hydrogen extraction technology. The acquisition serves as a proof of concept for the company's clean hydrogen energy solutions and aligns with the Ontario Hydrogen Innovation Fund's recent $30 million investment initiative. The fund supports projects integrating low-carbon hydrogen across various sectors. CEO Fabio Chianelli emphasized that this acquisition is crucial for validating their technology while positioning DiagnaMed to advance sustainable hydrogen development within Ontario's innovation ecosystem.

DiagnaMed Holdings (DGNMF) has acquired 91 unpatented mineral claims totaling 1,820 hectares in Ontario's Temiscamingue hydrogen district, adjacent to Quebec Innovative Materials Corp's (QIMC) project area. The strategic acquisition positions DiagnaMed to advance its proprietary hydrogen extraction technologies in one of Canada's most promising natural hydrogen regions.

The deal terms include a $25,000 non-refundable payment and the issuance of 12.5 million common shares. The sellers receive a 2% royalty on revenues from hydrogen or mineral sales, with an option for DiagnaMed to purchase 50% of the royalty for $2 million. The acquisition aims to foster collaboration with QIMC and accelerate technology commercialization in the region.

DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) has successfully closed its private placement offering, raising $397,510 through the issuance of 13,250,333 units at $0.03 per unit. Each unit includes one common share and one purchase warrant, allowing holders to acquire an additional share at $0.05 within 24 months.

The company paid $29,760.80 in finders' fees and issued 992,027 finder warrants. The net proceeds will fund research, development, and commercialization of their hydrogen production and monitor technology and BRAIN AGE® Brain Health AI Platform, along with general corporate purposes.

Chairman and CEO Fabio Chianelli participated in the offering, subscribing for 850,000 units ($25,500). This related party transaction is exempt from formal valuation and minority shareholder approval requirements as it represents less than 25% of the company's market capitalization.

DiagnaMed Holdings (OTCQB: DGNMF) has received FDA Orphan Drug Designation for molecular hydrogen in treating Amyotrophic Lateral Sclerosis (ALS). This designation supports the development of treatments for this rare neuromuscular disease that affects approximately 50,000 people in the U.S. and Europe, with over 5,000 new cases annually.

Molecular hydrogen, known for its antioxidant and anti-inflammatory properties, has shown promising results in preclinical studies for mitigating oxidative stress and inflammation in ALS progression. The designation provides key benefits including tax credits for clinical trials, FDA fee exemptions, and potential seven-year market exclusivity upon approval.

Additionally, DiagnaMed has entered a non-binding letter of intent with Revive Therapeutics dated February 28, 2025, to acquire full rights to DiagnaMed's intellectual property related to molecular hydrogen for ALS. The acquisition is expected to close by March 31, 2025, subject to due diligence and definitive agreement.